Health Monitor: Fascination for Slimness Has Racial Origins, Not Linked to Health  |  Parent Interventions: Online Brain Games Help in Multi-Tasking at Old Age   |  National Edu News: Intellectual Property Talent Search Exam 2019-20  |  Teacher Insights: Interactive Anatomy Learning Using Virtual Dissection  |  International Edu News: Climate change concern at internship meet  |  National Edu News: Kuwait demands NBA approval of degrees  |  Teacher Insights: Lower returns prompt higher risk-taking  |  Science Innovations: Egg shells help repair bones   |  Teacher Insights: Music and Movements Help Pre-School Children Learn Better  |  Teacher Insights: Gamification Found to be Useful for Dental, Medical Education  |  Parent Interventions: Social Anxiety in Children May be Due to Low and Advanced Emotional Intelligence  |  International Edu News: University of Toronto Ranked Again as Top University of Canada   |  National Edu News: IGNOU Declares Results for June Term End Exams  |  Science Innovations: Couples May be Able Choose the Gender of Offspring With Sperm Sorting Method  |  Management lessons: Recycling of Rice Straw Helps Control C02 Emissions in North Western India  |  
  • Pallikkutam Magazine
  • Companion Magazine
  • Mentor
  • Smart Board
  • Pallikkutam Publications

January 22, 2018 Monday 04:05:00 PM IST

Test vaccine for malaria appears promising

Health Monitor

London: A new, experimental vaccine for malaria has shown fast and effective results against acute infection, protection against relapse, as well as, delay in resistance formation, researchers say.

According to the World Health Organisation (WHO), nearly half of the world's population is at risk of malaria. In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths.

Researchers from the University of Tubingen in Germany, tested the efficacy, tolerability and safety of a combination of the drugs Fosmidomycin and Piperaquine on 83 patients in the phase II clinical trials.

The two-fold medication was administered for three days to patients aged one to 30, who were infected with malaria via the Plasmodium falciparum pathogen. In the 83 cases, there was a 100 per cent cure rate, said Peter Kremsner, Professor at the varsity.


Patients tolerated the treatment well, and it led to a swift reduction of clinical symptoms. "This study represents a milestone in the clinical research into Fosmidomycin," Kremsner said. 

The antibiotic Fosmidomycin, is originally isolated from Streptomyces lavendulae -- a species of bacteria from the genus Streptomyces. Streptomyces lavendulae blocks a metabolic pathway for the production of Isoprenoid -- naturally occurring organic chemicals -- in the malaria pathogen. 

This makes the malaria pathogen unable to metabolise or reproduce. As Isoprenoids are formed via a different synthesis path in the human body, humans have no target structures for Fosmidomycin. 

As a result, humans tolerate the drug well and suffer barely any side effects, the researchers said, in a paper published in Clinical Infectious Diseases. In addition, this unique mechanism excludes the possibility of cross-resistance to the drugs used in earlier malaria treatments.


The new combination also meets WHO guidelines for combination therapies. The two drugs mechanisms against differing target structures means that they attack the parasite in the bloodstream independently of one another. 

This meets WHO requirements for a fast and effective treatment of the acute phase of infection, and for protection against relapse due to reappearance of the infection. 

Furthermore, the effective mechanism helps to delay the formation of a possible resistance, the researchers noted.


Comments